Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Efavirenz,Emtricitabine,Tenofovir Disproxil Fumurate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Strides Receives USFDA Approval for Efavirenz, Emtricitabine & Tenofovir Disoproxil Fumurate Tablets
Details : Efavirenz/ Emtricitabine/tenofovir disoproxil fumarate) tablets a combination of 2 nucleoside analog HIV-1 reverse transcriptase inhibitors and 1 non-nucleoside HIV-1 reverse transcriptase inhibitor, for the treatment of HIV-1 infection.
Brand Name : Atripla-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 04, 2023
Lead Product(s) : Efavirenz,Emtricitabine,Tenofovir Disproxil Fumurate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?